[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Mental Health Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":575},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,58,0,25,[9,49,75,93,114,139,158,189,213,231,251,278,299,326,348,369,388,408,432,459,480,498,513,532,554],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100551218","cerebellum-prefrontal-paired-pulse-stimulation-for-methamphetamine-use-disorder-100551218",false,"NCT06457230","Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder","Exploring the Mechanisms and Efficacy of Cerebellum-Medial Prefrontal Cortex-Based Paired-Pulse Repetitive Transcranial Magnetic Stimulation for Methamphetamine Use Disorder","Inclusion Criteria\n\nParticipants will be eligible for inclusion if they meet the following criteria:\n\n1. Methamphetamine is the primary substance of use, and the participant meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for moderate or severe methamphetamine use disorder;\n2. aged 18 to 60 years;\n3. normal or corrected-to-normal vision and hearing, and right-handedness;\n4. primary school education or above, with the ability to understand the questionnaires and behavioral task instructions.\n\nExclusion Criteria\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. presence of metal objects in the body, such as metal dentures, orthodontic braces, bone fixation plates, aneurysm clips, or other metallic implants;\n2. severe physical illness or chronic disease, including heart disease, severe hypertension, stroke, epilepsy, or history of head trauma;\n3. comorbid psychiatric disorders, such as bipolar disorder, schizophrenia, or severe depression;\n4. previous participation in transcranial magnetic stimulation- or electroencephalography-related studies;\n5. refusal to participate in the study, poor compliance, or any other contraindications to transcranial magnetic stimulation.",true,"MALE","18 Years","60 Years",{"count":22,"type":23},90,"ESTIMATED","INTERVENTIONAL",[26],"NA","To investigate the mechanism and efficacy of a novel repetitive transcranial magnetic stimulation (rTMS) intervention model with paired cerebellar-medial prefrontal cortex (mPFC) pulses on methamphetamine use disorder patients and to develop a novel physiotherapeutic intervention to optimise the treatment and management.",[29],"Methamphetamine Use Disorder",[31,32,33,34,35],"Repetitive transcranial magnetic stimulation","Cerebellum","Methamphetamine","Cortico-Cortical Paired Associative Stimulation","medial prefrontal cortex","RECRUITING","2026-06-21",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2024-12-24",{"date":44,"type":23},"2026-09",{"name":46,"class":47},"Shanghai Mental Health Center","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100585571","efficacy-and-mechanisms-of-tus-on-cognitive-deficits-in-schizophrenia-based-on-the-hippocampal-prefrontal-circuit-100585571","NCT06904092","Efficacy and Mechanisms of TUS on Cognitive Deficits in Schizophrenia: Based on the Hippocampal-Prefrontal Circuit","Efficacy and Mechanisms of Transcranial Ultrasound Stimulation (TUS) on Cognitive Deficits in Schizophrenia：Based on the Hippocampal-Prefrontal Circuit","Inclusion Criteria:\n\n* Meet the DSM-5 diagnostic criteria for schizophrenia ;\n* Age18-50, right-handed, Han nationality;\n* Presence of cognitive deficit: defined as d' value \\\u003C0.5 in associative memory test;\n* Be in a stable condition, received second-generation antipsychotics for at least 4 weeks or more;\n* Written informed consent;\n\nExclusion Criteria:\n\n* Current or past neurological illness, severe physical diseases, substance abuse or alcohol dependence, mental retardation, pregnancy or lactation;\n* Uncooperative or risky patients with high excitement, stupor, disorder of words and deeds, negative suicide, etc.;\n* History of MECT or other physical therapy within 6 months;\n* History of epilepsy, or epileptic waves on the baseline EEG;\n* Ruled out share antiepileptic drugs (carbamazepine, valproic acid salt) or larger doses of benzodiazepine drugs (diazepam \\> 10mg\u002Fday, clonazepam \\> 2mg\u002Fday etc.), if necessary, remain unchanged during the course of treatment;\n* Contraindications to TUS and MRI are present.","ALL","50 Years",{"count":59,"type":23},140,[26],"Cognitive deficit is a core symptom of schizophrenia related to poorer functional outcome. Prior studies indicated that abnormalities in the hippocampus-prefrontal circuit and glutamate\u002FGABA imbalances may lead to cognitive deficits. Based on the current background and our previous studies, it has been proved that TUS can modulate neural excitability and plasticity in the hippocampus. In this double-blind, randomized study, the efficacy of different treatment options and mechanisms of TUS on cognitive deficits will be investigated.",[63],"Cognitive Deficit in Schizophrenia",[65],"Schizophrenia; Cognitive Deficit; Transcranial Ultrasound Stimulation; Hippocampus- Prefrontal Circuit","NOT_YET_RECRUITING","2026-06-10",{"date":69,"type":40},"2026-06-12",{"date":71,"type":23},"2026-07-01",{"date":73,"type":23},"2027-12-31",{"name":46,"class":47},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":57,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":48},"100643368","the-efficacy-and-safety-of-temporal-interference-stimulation-in-the-treatment-of-post-traumatic-stress-disorder-100643368","NCT07644338","The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of Post-Traumatic Stress Disorder","Inclusion Criteria:\n\n1. Age 18-50 years, male or female\n2. Diagnosis of PTSD per DSM-5 (assessed by CAPS-5), with symptom duration of at least 3 months, and PTSD as the current primary diagnosis; comorbid depressive disorder or anxiety disorder is allowed\n3. If currently receiving psychiatric medication, the dosage must be stable for at least 4 weeks prior to enrollment\n4. At least 9 years of education (junior high school or above)\n\nExclusion Criteria:\n\n1. Any DSM-5 diagnosis other than PTSD, depressive disorder, or anxiety disorder\n2. PTSD symptoms too severe to complete required assessments\n3. Received electroconvulsive therapy (ECT) within the past 6 months\n4. Received any other form of neuromodulation within the past 2 months (see Item 3 for ECT)\n5. Severe medical illness or any condition that may induce seizures or intracranial hypertension (e.g., cardiovascular or respiratory diseases)\n6. History of neurological disorders (e.g., epilepsy, cerebrovascular accident) or brain injury\u002Fsurgery\n7. Presence of intracranial stents, cardiac pacemakers, coronary stents, cochlear implants, or any other MRI-incompatible implants\n8. Current significant suicidal behavior risk per investigator judgment\n9. Pregnancy or planning to become pregnant during the study period\n10. Initiation of structured psychotherapy for PTSD within 3 months prior to screening, with expected change during the 10-week treatment period",{"count":82,"type":23},5,[26],"This study aims to evaluate the efficacy and safety of Temporal Interference (TI) stimulation in treating patients with post-traumatic stress disorder (PTSD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) ,magnetoencephalography（MEG）,electroencephalography (EEG).",[86],"Post-traumatic Stress Disorder (PTSD)","2026-06-08",{"date":69,"type":40},{"date":87,"type":40},{"date":91,"type":23},"2027-06",{"name":46,"class":47},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":17,"sex":56,"minAge":19,"maxAge":20,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100610484","effect-of-high-intensity-transcranial-alternating-current-stimulation-on-gambling-disorder-a-randomized-controlled-trial-100610484","NCT07228182","Effect of High-Intensity Transcranial Alternating Current Stimulation on Gambling Disorder: A Randomized Controlled Trial","HITACSRCT-GD","Inclusion Criteria:\n\n* Aged 18-60, male or female, with 9 or more years of education, and able to complete questionnaire evaluation and behavioral tests;\n* Meet DSM-5 (Diagnostic and Statistical Manual of mental disorders，DSM) diagnostic criteria for gambling disorder;\n* Have gambled for at least one year (at least once a week);\n* Normal vision and hearing, or within the normal range after correction;\n* Agree to cooperate in the follow-up evaluation;\n* No metal implantation in the head, no history of nerve problems or head injury, and no skin sensitivity.\n\nExclusion Criteria:\n\n* Have severe cognitive impairment, such as a history of head trauma, -cerebrovascular disease, epilepsy, etc.;\n* Have used drugs promoting cognitive function in the last 6 months;\n* Have impaired intelligence (Intelligence Quotient\\\u003C70);\n* Abuse or dependence of psychoactive substances (except nicotine) in the last 5 years.",{"count":101,"type":23},60,[26],"The investigators assume that High-intensity transcranial Alternating Current Stimulation (HI-tACS) could improve gambling disorder patients' executive-control function by modulating abnormal neural activity, particularly gamma-band oscillations, which are closely associated with executive-control deficits. This study intends to validate the effect of HI-tACS treatment, which has been discovered in the previous pilot study. A three-month follow-up assessment will be conducted to test the changes in executive-control function and its underlying mechanism.",[105],"Gambling Disorder",[107],"High-Intensity Transcranial Alternating Current Stimulation, Gambling disorder.",{"date":67,"type":40},{"date":110,"type":23},"2026-06-01",{"date":112,"type":23},"2026-12-28",{"name":46,"class":47},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":48},"100451503","mental-health-during-the-whole-life-cycle-of-community-patients-with-schizophrenia-100451503","NCT05159349","Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia","Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia: a Cohort Study","Inclusion Criteria:\n\n* Registered in the Shanghai Mental Health Information Management System.\n* Meets criteria for the diagnosis of schizophrenia (ICD-10 or ICD-11).\n* Patients with schizophrenia diagnosed within five years.\n* Aged between 18 and 65 years.\n\nExclusion Criteria:\n\n* Patients with severe physical diseases and organic brain diseases.\n* The patient is about to settle outside Shanghai.","65 Years",{"count":123,"type":23},1200,"OBSERVATIONAL","Schizophrenia is one of the components of severe mental disorders. It has the characteristics of prolonged course, low cure rate, high recurrence rate and high disability rate. It brings many short-term and long-term effects to individuals, families and society. Studies on patients with schizophrenia mainly focus on cross-sectional and case-control studies, but there is a lack of long-term follow-up of patients with schizophrenia in the community. Therefore, this study would establish a cohort study to solve the chronological relationship between exposure and effect, focus on community schizophrenia, and establish a community schizophrenia patient biobank that has been tracked for a long time from diagnosis.",[127],"Schizophrenia",[127,129,130,131],"Cohort study","The whole life cycle","Mental health","2026-06-04",{"date":87,"type":40},{"date":135,"type":40},"2021-12-01",{"date":137,"type":23},"2027-12",{"name":46,"class":47},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":121,"enrollmentInfo":146,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":4},"100639183","multimodal-pharmacological-study-of-clinical-cohorts-for-major-depressive-disorder-100639183","NCT07602153","Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder","Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder - Sub-task 2: A Longitudinal Imaging-Proteomics Study on Suicidal Tendency and Mechanisms of Rapid Antidepressant Effects","Inclusion Criteria:\n\nAge 18-65; Han Chinese; meets DSM-5 criteria for MDD; suicidal ideation (HAMD-17 Item 3 score ≥ 2); education above primary school; provided written informed consent.\n\nExclusion Criteria:\n\nOther major mental disorders; unstable physical diseases (cardiovascular, hepatic, etc.); pregnancy or lactation; contraindications to Ketamine or ECT; history of drug or alcohol abuse within 6 months.",{"count":147,"type":23},130,"This study focuses on the neurobiological changes in MDD patients with high suicidal risk during rapid antidepressant treatments, such as Esketamine and Electroconvulsive Therapy (ECT). Core ObjectivesEstablish a standardized longitudinal cohort for high-risk suicidal populations to ensure high-quality data for clinical transformation. Investigate the biological mechanisms of rapid-acting interventions by analyzing changes in brain function and molecular pathways. Develop predictive biomarkers to identify treatment responders early, thereby reducing ineffective trial-and-error treatments and lowering suicide risk. Methodology \\& Data CollectionThe study integrates multi-dimensional data across three critical time points: T0 (Baseline), T1 (Acute Phase\u002F24h post-first treatment), and T2 (Remission Phase\u002F4-6 weeks). Sample Cohort: A total of 130 participants (70 ECT, 30 Esketamine, 30 conventional medication). Multimodal Data Integration:Clinical Phenotyping: Standardized scales including HAMD-17 (Primary Indicator), C-SSRS (Suicide Assessment), and QIDS-SR16. Biological Omics: Whole Genome Sequencing (WGS), single-cell sequencing, proteomics, metabolomics, DNA methylomics, and gut metagenomics. Neuroimaging \\& Physiology: Functional MRI (fMRI), Diffusion Tensor Imaging (DTI), and 32-channel resting-state EEG. SignificanceBy capturing dynamic \"treatment-response\" trajectories, the project aims to move beyond descriptive symptoms to a system biology-based diagnosis. The findings are expected to provide scientific evidence for individualized intervention strategies and improve the efficiency of care for patients with treatment-resistant depression and acute suicidal ideation.",[150],"Major Depressive Disorder (MDD","2026-05-17",{"date":153,"type":40},"2026-05-22",{"date":155,"type":23},"2026-05-30",{"date":73,"type":23},{"name":46,"class":47},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":56,"minAge":57,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":48},"100635606","phase-1-study-of-neural-stem-cell-derived-exosomes-in-moderate-to-severe-early-onset-alzheimers-disease-100635606","NCT07554872","Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease","A Phase I, Open-Label, Single-Center, Frequency-Escalation Study of the Safety, Tolerability, and Preliminary Efficacy of Neural Stem Cell-Derived Exosomes in Patients With Moderate-to-Severe Early-Onset Alzheimer's Disease","* Inclusion Criteria:\n* Male or postmenopausal female, aged 50 to 75 years.\n* Meets the 2011 NIA-AA criteria for probable Alzheimer's disease dementia.\n* Age at onset ≤65 years.\n* CMMS score 5-20\n* Stable dose for at least 2 months before enrollment if receiving pro-cognitive or psychiatric medications.\n* Primary school education or above and able to complete study-required cognitive assessments.\n* Hachinski Ischemic Score ≤4.\n* GDS-30 total score ≤10.\n* Screening brain MRI+DWI+SWI meeting protocol-defined cerebrovascular exclusion thresholds and no major structural abnormalities inconsistent with Alzheimer's disease.\n* Positive amyloid pathology confirmed by Aβ-PET at screening or before enrollment.\n* Adequate vision and hearing to complete assessments.\n* Has a reliable caregiver able to accompany the participant to study visits and provide information for assessments.\n* Willing to participate and sign informed consent.\n\nExclusion Criteria:\n\n* Dementia due to causes other than Alzheimer's disease.\n* Brain MRI showing any of the following: Fazekas white matter hyperintensity score \\>2; more than 2 lacunar infarcts \\>1.5 cm; lacunar infarcts involving critical regions such as the thalamus, hippocampus, entorhinal cortex, or parahippocampal region; cerebral hemorrhage, subdural hematoma, aneurysm, arteriovenous malformation, intracranial mass lesion, or other clinically significant structural abnormalities.\n* Allergy to stem cell-derived exosomes or PET examination.\n* Severe psychiatric disorder or symptoms.\n* Significant active physical illness, including severe cardiac disease, severe systemic infection, or severe liver\u002Fkidney dysfunction.\n* Elevated tumor markers or tumor history.\n* Immune-related disease.\n* Significant nasal obstruction.\n* Serious suicide risk.\n* Participation in another clinical trial or stem cell therapy within the past 6 months.\n* Any other condition judged inappropriate by the investigator.\n* Contraindications to MRI or inability to complete MRI examinations, including non-MRI-compatible metallic implants, certain stents, plates, pacemakers, or severe claustrophobia.","75 Years",{"count":167,"type":23},9,[169],"PHASE1","This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease. The study aims to evaluate the safety, tolerability, and preliminary efficacy of neural stem cell-derived exosomes (NSC-EVs) administered by the intranasal route. A total of 9 participants will be enrolled in 3 frequency-escalation groups: once every 3 days, once every other day, and once daily, each for 28 days. Participants will undergo screening and baseline assessment, a 28-day treatment period, and follow-up visits at 4, 8, and 24 weeks after the end of treatment.",[172],"Alzheimer Disease (AD)",[174,175,176,177,178,179,180,181],"Early-Onset Alzheimer's Disease","Moderate-to-Severe Alzheimer's Disease","Neural Stem Cell-Derived Exosomes","Intranasal Administration","Phase I Clinical Study","Frequency Escalation","Safety","Tolerability","2026-05-13",{"date":184,"type":40},"2026-05-15",{"date":186,"type":23},"2026-05",{"date":137,"type":23},{"name":46,"class":47},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":24,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":48},"100635799","the-effect-of-game-based-intervention-on-the-cognition-of-schizophrenia-patients-100635799","NCT07557381","The Effect of Game-Based Intervention on the Cognition of Schizophrenia Patients","The Effect of a 2-month Somatic Serious Games on the Cognition of Schizophrenia Patients","Inclusion Criteria:\n\n1. Registered in the Shanghai Mental Health Information Management System and hospitalized in the designated district-level mental health center wards;\n2. Schizophrenia patients meeting the diagnostic criteria of schizophrenia in the International Classification of Diseases (ICD-10);\n3. 18 - 45 years old;\n4. Good self-care ability;\n5. Clinically stable (without acute exacerbation) for at least 1 week before enrollment, with a stable dose of antipsychotic drugs or other concomitant psychotropic drugs for at least 1 week;\n6. No hand disabilities, and can use mobile phones or tablets normally;\n7. Have a primary school education or above;\n8. Normal vision and hearing, or within the normal range after correction;\n9. Own and be able to independently use a smart phone or other electronic devices;\n10. Patients and their families have given informed consent to this study, and voluntarily cooperate to participate in the intervention and sign the informed consent form.\n\nExclusion Criteria:\n\n1. not reside in Shanghai after discharge;\n2. suffering from serious physical or brain organic diseases;\n3. comorbid with other psychotic disorders.","45 Years",{"count":198,"type":23},84,[26],"Schizophrenia is a common and severe mental disorder that imposes a significant burden on patients. Cognitive impairment can be regarded as one of the core symptoms of schizophrenia, which is prevalent among patients with schizophrenia. In recent years, digital rehabilitation therapy based on games has shown a remarkable development trend among schizophrenia patients. Serious games, or application games, refer to those games aimed not only for entertainment. They can educate, train, or change the behavior of players through interesting intervention forms and have been applied in many healthcare fields. This study aims to develop a somatosensory interactive game for patients with cognitive impairment of schizophrenia to improve their cognitive functions and verify its effectiveness and feasibility through a randomized controlled trial.",[127],[203,127,204],"Cognition","Game-Based Intervention","2026-05-05",{"date":207,"type":40},"2026-05-11",{"date":209,"type":40},"2026-04-19",{"date":211,"type":23},"2028-07",{"name":46,"class":47},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":196,"enrollmentInfo":219,"targetDuration":4,"studyType":24,"phases":220,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":229,"leadSponsor":230,"locationsCount":48},"100635798","effects-of-gamified-rehabilitation-on-cognitive-and-psychosocial-outcomes-in-inpatients-with-schizophrenia-100635798","NCT07557368","Effects of Gamified Rehabilitation on Cognitive and Psychosocial Outcomes in Inpatients With Schizophrenia","Effects of Gamified Rehabilitation on Cognitive and Psychosocial Outcomes in Inpatients With Schizophrenia: A Randomized Controlled Trial[",{"count":198,"type":23},[26],"Schizophrenia is a severe and chronic mental disorder that profoundly impacts patients' psychological, social, and occupational functions. Cognitive impairment is a core symptom that severely limits daily living abilities. Systematic rehabilitation is crucial for delaying disease progression and improving social functions.\n\nTraditional rehabilitation typically relies on pharmacological treatments and conventional cognitive remediation therapies. However, cognitive training alone rarely translates spontaneously into real-world functional improvement; integration with functional skills training is generally required before meaningful gains in daily living are achieved. Furthermore, traditional interventions are typically delivered in contexts detached from patients' everyday lives and are often perceived as monotonous, resulting in poor treatment adherence and compromised long-term rehabilitation outcomes.\n\nWith the development of digital health technologies, gamified interventions offer new opportunities for psychiatric rehabilitation. Among these innovative approaches, integrating psychoeducation with interactive storytelling has shown unique advantages. Such immersive narrative contexts can effectively enhance patients' illness awareness, treatment motivation, and medication adherence. Nevertheless, existing digital tools still have room for improvement. On one hand, many applications are confined to static screen-based interactions, overlooking the elevated somatic disease burden and sedentary risks prevalent in this population. On the other hand, existing applications rarely successfully integrate cognitive interventions with coherent psychosocial interventions, making it difficult for cognitive improvements to genuinely translate into real-life skills.\n\nTo this end, the present study developed an interactive digital rehabilitation application specifically designed for individuals with schizophrenia. This intervention innovatively combines cognitive remediation with psychosocial rehabilitation through two distinct yet highly complementary modules: a sensory-motion cognitive module, which leverages the built-in motion-sensing capabilities of mobile devices to engage patients in moderate physical activity while performing cognitive tasks; and an interactive narrative module, encompassing medication management, symptom management, psychological recovery, and social rehabilitation. Through a randomized controlled trial, this study evaluates the practical effectiveness of this multimodal approach in improving patients' overall rehabilitation outcomes, ultimately seeking to provide a highly engaging rehabilitation pathway that facilitates the transfer of skills to daily life.",[127],[224,127,225,226],"Gamified Rehabilitation","Cognitive","Psychosocial",{"date":207,"type":40},{"date":209,"type":40},{"date":211,"type":23},{"name":46,"class":47},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":17,"sex":56,"minAge":19,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":250,"locationsCount":48},"100638677","an-exploratory-study-on-the-prediction-of-recurrence-risk-of-bipolar-disorder-using-sentiment-analysis-technology-based-on-multi-modal-feature-fusion-100638677","NCT07573839","An Exploratory Study on the Prediction of Recurrence Risk of Bipolar Disorder Using Sentiment Analysis Technology Based on Multi-modal Feature Fusion","Patients group inclusion criteria:\n\n* Patients who have previously met or currently meet the diagnostic criteria for bipolar disorder according to DSM-5, whose condition and treatment are currently stable, and who cooperate with the assessment;\n* Age ≥18 years, \\\u003C65 years;\n* Han Chinese ethnicity;\n* Sufficient visual and auditory abilities to complete the necessary examinations for the study;\n* Understanding the study content and signing the informed consent form. If the patient is unable to sign the informed consent form personally due to low education level or other reasons, it may be signed by a relative or guardian on their behalf.\n\nexclusion criteria:\n\n* The presence of intellectual disability or other conditions that significantly affect the patient's current mental state;\n* the patient has a serious or unstable physical illness, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension (including untreated or uncontrolled hypertension), malignant tumors, immunodeficiency, and blood glucose levels higher than 12 mmol\u002FL; or other diseases that may interfere with the test assessment (abnormal indicators more than twice the normal value).\n\nHealthy controls group inclusion criteria:\n\n* Age ≥ 18 years, \\\u003C 65 years;\n* Han Chinese ethnicity;\n* Gender matched to the patient group;\n* Sufficient visual and auditory ability to complete the necessary examinations for the study;\n* Understanding of the study content and signing of informed consent;\n* No family history of mental illness. exclusion criteria:\n* Individuals with a mental disorder conforming to DSM-5, or those with suspicious mental symptoms but not meeting the diagnostic criteria;\n* Individuals with severe physical illness that makes it difficult to complete the necessary examinations.","64 Years",{"count":239,"type":23},400,"Bipolar disorder (BD) has become a significant public health problem with complex clinical manifestations, difficult treatment, and poor prognosis. However, there is still a lack of effective biological markers for diagnosing and predicting recurrence. Sentiment analysis computing usually refers to using machine equipment to classify, identify, interpret, and imitate human emotions. However, current multi-modal emotion analysis research is mainly based on one or two modalities. Due to the diversity and complexity of patients' emotional expressions, this single- and dual-modal information analysis is far from enough for accurate discrimination of emotional symptoms. Only emotion analysis technology based on multi-modal feature fusion can make more precise and effective judgments. The current project is based on our previous research on cognitive neuroimaging and big data analysis of bipolar disorder. The investigators plan to enroll 200 BD patients who meet DSM-5 diagnostic criteria and 200 healthy controls. The investigators will use sentiment analysis technology with multi-modal feature fusion (text data, audio and visual modalities, eye movements, and electrophysiology) to identify BD recurrence. Biological markers for risk prediction and an algorithm model for joint judgment of multi-source information will be established to analyze the characterization data. The effectiveness of this recurrence prediction model will be further verified and optimized through a large-sample, prospective cohort study design. It is hoped that it can provide a new method for predicting the recurrence risk of BD patients. In the near future, clinical decision-making aids based on this auxiliary method can be developed, and the translational application value of clinical diagnosis and treatment can be explored.",[242,243],"Bipolar Disorder (BD)","Healthy Control","2026-05-01",{"date":246,"type":40},"2026-05-07",{"date":248,"type":23},"2026-04",{"date":137,"type":23},{"name":46,"class":47},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":56,"minAge":258,"maxAge":196,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":48},"100635930","multi-target-tms-for-schizophrenia-negative-symptoms-100635930","NCT07559084","Multi-target TMS for Schizophrenia Negative Symptoms","Development of a Multi-target Transcranial Magnetic Intervention Technique for Negative Symptoms of Schizophrenia","Inclusion Criteria:\n\n1. Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center;\n2. Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment;\n3. Male or female aged 16-45 years;\n4. Education duration ≥ 9 years;\n5. Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit;\n6. Participants and their guardians can understand and sign written informed consent;\n7. Total score on the PANSS Negative Symptom subscale (PANSS-N) \\> 15, and at least one item score ≥ 3.\n\nExclusion Criteria:\n\n1. Current or lifetime psychiatric disorders as determined by SCID-5 assessment;\n2. Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions;\n3. Alcohol abuse within 30 days prior to the study or alcohol\u002Fdrug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline;\n4. Pregnant or breastfeeding women;\n5. Intellectual disability (IQ \\\u003C 70).","16 Years",{"count":260,"type":23},64,[26],"This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the left dorsolateral prefrontal cortex (L-DLPFC), left inferior parietal lobule (L-IPL), and right orbitofrontal cortex (R-OFC) for negative symptoms of schizophrenia.",[264],"SCHIZOPHRENIA 1 (Disorder)",[266,267,268,269,270],"schizophrenia","TMS","repetitive transcranial magnetic stimulation","rTMS","TBS","2026-04-26",{"date":273,"type":40},"2026-04-30",{"date":244,"type":23},{"date":276,"type":23},"2028-01-30",{"name":46,"class":47},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":20,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":48},"100634852","the-efficacy-of-an-ai-based-rehabilitation-treatment-in-patients-with-anxiety-disorders-100634852","NCT07545070","The Efficacy of an AI-Based Rehabilitation Treatment in Patients With Anxiety Disorders","A Randomized Controlled Trial Protocol Testing the Efficacy of an AI-Based Rehabilitation Treatment in Patients With Anxiety Disorders","1\\. Subjects with anxiety disorders\n\n* Inclusion Criteria:\n\n  * In accordance with ICD-11 for Anxiety Disorders;\n  * Between the ages of 18-60;\n  * Completed at least 9 years of education;\n  * Ability to use computers or smartphone;\n  * Native Chinese speaker;\n  * Signing informed consent.\n* Exclusion Criteria:\n\n  * With severe psychiatric symptoms requiring hospitalization, or unable to complete the required assessment and treatment;\n  * Use of cognitive-enhancing medications within the past 6 months;\n  * With intellectual, visual, or auditory impairments that affect their ability to interact with aided-diagnostic systems.",{"count":286,"type":23},158,[26],"The trail aimed to test the efficacy of AI-based rehabilitation treatment in patients with anxiety disorders. Specifically, the objective of this trial is to determine whether the AI-based rehabilitation combined with treatment as usual is more effective than treatment as usual alone in improving outcomes in patients with anxiety disorders.",[290],"Anxiety Disorders","2026-04-15",{"date":293,"type":40},"2026-04-22",{"date":295,"type":23},"2026-04-25",{"date":297,"type":23},"2026-12-25",{"name":46,"class":47},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":17,"sex":56,"minAge":19,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":24,"phases":309,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":323,"leadSponsor":325,"locationsCount":48},"100629879","neural-mechanisms-of-the-sensorymotor-circuit-in-sensory-phenomena-in-ocd-100629879","NCT07480408","Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD","Neural Mechanisms of the Insula-Supplementary Motor Area Circuit in Sensory Phenomena in Obsessive-Compulsive Disorder","Inclusion Criteria:\n\nOCD with abnormal sensory phenomena\n\n1. Meet the diagnostic criteria for Obsessive-Compulsive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.\n2. Aged 18-55 years.\n3. Score ≥16 on the Yale-Brown Obsessive Compulsive Scale, indicating moderate to severe symptoms.\n4. Score \\>6 on the Sensory Phenomena Scale (SPS), indicating moderate to severe sensory phenomena.\n5. Right-handed.\n6. Either medication-free or on stable medication for at least 8 weeks.\n\nOCD without abnormal sensory phenomena\n\n1. Meet the diagnostic criteria for Obsessive-Compulsive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.\n2. Aged 18-55 years.\n3. Score ≥16 on the Yale-Brown Obsessive Compulsive Scale.\n4. Score ≤6 on the Sensory Phenomena Scale (SPS).\n5. Right-handed.\n6. Either medication-free or on stable medication for at least 8 weeks.\n\nExclusion criteria\n\n1. Meeting diagnostic criteria in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition for psychiatric disorders other than OCD or obsessive-compulsive personality disorder.\n2. OCD symptoms so severe that required assessments cannot be completed.\n3. Presence of severe suicidal ideation or high suicide risk.\n4. Pregnant women or women planning pregnancy in the near future.\n5. History of epilepsy or any medical condition that may induce seizures or intracranial hypertension.\n6. Contraindications to MRI, such as metallic implants.\n7. Clinically significant medical illnesses or abnormal laboratory findings.\n8. Inability to complete study procedures due to severe symptoms, low cognitive functioning, or poor cooperation.\n\nHealthy Controls Inclusion criteria\n\n1. No current or past psychiatric disorders meeting diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.\n2. Aged 18-55 years.\n3. Right-handed. Exclusion criteria\n\n1\\. Pregnant women or women planning pregnancy in the near future. 2. History of epilepsy or any medical condition that may induce seizures or intracranial hypertension.\n\n3\\. Presence of severe suicidal ideation or high suicide risk. 4. Contraindications to MRI, such as metallic implants. 5. Clinically significant medical illnesses or abnormal laboratory findings. 6. Inability to complete study procedures due to severe symptoms, low cognitive functioning, or poor cooperation.","55 Years",{"count":308,"type":23},120,[26],"The goal of this clinical study is to investigate the neural mechanisms of abnormal sensory phenomena in patients with Obsessive-Compulsive Disorder and to evaluate whether modulation of the insula-supplementary motor area circuit can improve these symptoms. The study will include adult patients with OCD (with or without sensory phenomena) and healthy volunteers.\n\nThe main questions it aims to answer are:\n\n* Do patients with OCD show abnormal activity in the insula-SMA circuit compared with healthy controls?\n* Is this abnormality associated with the presence and severity of abnormal sensory phenomena?\n* Can low-frequency rTMS targeting the Supplementary Motor Area improve sensory phenomena and obsessive-compulsive symptoms? Researchers will compare an on-line rTMS group (viewing body-focused videos during stimulation) with an off-line rTMS group (resting during stimulation) to evaluate whether task engagement enhances treatment effects.\n\nParticipants will:\n\n* Complete clinical assessments and behavioral tasks.\n* Undergo EEG and fMRI assessments.\n* Receive low-frequency rTMS targeting the Supplementary Motor Area.\n* Repeat assessments after the intervention.",[312],"Obsessive - Compulsive Disorder",[314,315,316,317,318],"obsessive-compulsive disorder","sensory phenomena","supplementary motor area","insula","neuromodulation","2026-03-18",{"date":321,"type":40},"2026-03-20",{"date":244,"type":23},{"date":324,"type":23},"2028-12-31",{"name":46,"class":47},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":56,"minAge":258,"maxAge":306,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":48},"100630213","efficacy-and-influencing-factors-of-mindfulness-based-exposure-group-therapy-for-ocd-100630213","NCT07484750","Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD","Mindfulness-Based Exposure Group Therapy for Obsessive-compulsive Disorder: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Have a primary diagnosis of Obsessive-Compulsive Disorder (OCD) according to DSM-5 criteria\n* Are between 16 and 55 years of age (inclusive)\n* Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score ≥ 16\n* Have an education level of junior high school or above\n* Are medication-free or have been stabilized on psychotropic medication for at least 8 weeks\n* Have sufficient visual and auditory capabilities to complete study assessments\n* Are willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Meet DSM-5 criteria for any other psychiatric disorder besides OCD\n* Have severe OCD symptoms that prevent completion of assessments\n* Exhibit active suicidal ideation or high suicide risk\n* Have a serious somatic disease, central nervous system disease, or substance abuse history\n* Are pregnant, breastfeeding, or planning pregnancy\n* Have metal implants contraindicated for MRI (e.g., pacemakers, intracranial clips, metal dentures, arterial stents, joint fixations)",{"count":260,"type":23},[26],"Obessive-Compulsive Disorder (OCD) is frequently treatment-refractory and imposes a substantial burden on affected individuals. Although Exposure and Response Prevention (ERP) is widely regarded as the first-line intervention, its inherently distressing nature contributes to treatment refusal and premature dropout in a subset of patients. The present study aims to develop and validate a novel intervention, Mindfulness-Based Exposure Therapy (MBET).\n\nIn contrast to existing protocols that incorporate mindfulness as an adjunct to ERP and have yielded mixed or limited benefits, this study seeks a theoretically grounded integration of mindfulness and exposure-based principles. We hypothesize that mindfulness training improves emotion regulation, thereby producing a synergistic effect that enhances patients' capacity to engage in and complete exposure tasks.\n\nFrom a clinical perspective, MBET is intended to offer a more tolerable and acceptable alternative to standard ERP, with the potential to improve treatment adherence and clinical outcomes among patients who experience traditional exposure procedures as excessively distressing.",[337],"Obessive-Compulsive Disorder",[339,340],"mindfulness","Exposure and Response Prevention","2026-03-16",{"date":321,"type":40},{"date":344,"type":40},"2026-02-03",{"date":346,"type":23},"2029-06-30",{"name":46,"class":47},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":48},"100629284","transcranial-temporal-interference-stimulation-targeted-of-the-amygdala-as-an-intervention-for-alcohol-use-disorder-patients-100629284","NCT07472673","Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Patients","Exploring the Efficacy and Neural Mechanisms of Transcranial Temporal Interference Stimulation Modulating the Amygdala on Patients With Alcohol Use Disorder","Inclusion Criteria:\n\n* aged 18 to 60 years old;\n* Meets the DSM-5 diagnostic criteria for alcohol use disorder;\n* Normal or corrected normal vision and hearing;\n* Able to cooperate in completing the questionnaire assessment and behavioral tests;\n* No metal implantation in the head, no history of neurological problems or head injury.\n\nExclusion Criteria:\n\n* Suffering from severe cognitive dysfunction, such as a history of head trauma, cerebrovascular disease, epilepsy, etc., use of cognitive-promoting medications in the last 6 months;\n* serious physical or neurological illness, a diagnosis of any other psychiatric disorder under DSM-5 criteria (except for nicotine use disorder); Other psychoactive substance abuse or dependence in the last 5 years (except nicotine).\n* any contraindications to transcranial electrical stimulation.",{"count":101,"type":23},[26],"The purpose of this research is to investigate the efficacy of transcranial temporal interference stimulation (tTIS) targeting the amygdala in patients with alcohol use disorder.",[359],"Alcohol Use Disorder",[361],"Alcohol use disorder","2026-03-12",{"date":341,"type":40},{"date":365,"type":23},"2026-02-15",{"date":367,"type":23},"2026-12-31",{"name":46,"class":47},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":121,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":386,"locationsCount":387},"100618664","transcranial-electrical-stimulation-for-comorbid-depression-and-chronic-pain-100618664","NCT07334561","Transcranial Electrical Stimulation for Comorbid Depression and Chronic Pain","Transcranial Electrical Stimulation for Comorbid Depression and Pain: From Technological Development to Clinical Translation in a Multicenter Trial","Inclusion Criteria:\n\n1. Aged 18-65 years;\n2. Meet the diagnostic criteria for a depressive episode according to DSM-5, with current mild-to-moderate depressive symptoms (HAMD-17 score ≥8 and ≤23);\n3. Report persistent pain lasting ≥3 months and score ≥4 on item 5 of the Brief Pain Inventory (BPI);\n4. Maintain a stable anti-depression drug and psychological treatment plan (including dosage, drug type, or therapeutic approach) for at least four weeks prior to enrollment;\n5. Right-handed, with normal hearing, vision, or corrected vision;\n6. Able to voluntarily provide written informed consent to participate in the study and willing and capable of complying with all study procedures.\n\nExclusion Criteria:\n\n1. Diagnosed with other psychiatric disorders, including schizophrenia spectrum disorders, bipolar I disorder (due to potential risk of manic episodes and contraindication of lithium or anticonvulsants), primary anxiety disorders, depression associated with severe somatic illness, etc.\n2. Active suicidal ideation, defined as a score of 4 on item 3 of the HAMD-17.\n3. Severe or treatment-resistant depression (HAMD-17 score ≥23, with current depressive episode lasting at least 2 years or failure to respond to two or more antidepressant treatments during the current episode).\n4. Substance use disorder within the past 3 months.\n5. Experience of malignant pain due to cancer pain syndrome, visceral pain (e.g., gastric pain), or referred pain (e.g., back pain from pancreatitis).\n6. Neurological disorders associated with structural brain abnormalities (e.g., traumatic brain injury, recent stroke, brain tumor).\n7. Having undergone neuromodulation treatments within the past 3 months, including electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (rTMS), or transcranial electrical stimulation (tES).\n8. Contraindications to transcranial electrical stimulation (e.g., intracranial metal implants, cardiac pacemaker, cochlear implant, skin lesions at stimulation sites, personal or family history of epilepsy).\n9. Current or within the past 1 month use of medications affecting central nervous system excitability or pain, such as anticonvulsants, lithium, opioids, nonsteroidal anti-inflammatory drugs, and antipsychotics. Occasional as-needed use of acetaminophen as rescue medication is permitted but must be documented in detail in the study diary.\n10. Signs of dementia or other severe cognitive impairment (MMSE score \\\u003C24).\n11. Severe or unstable somatic diseases, including but not limited to: neurological disorders (e.g., epilepsy, stroke, migraine, history of cranial surgery); cardiovascular diseases (e.g., uncontrolled hypertension, heart failure, arrhythmia, myocardial infarction); respiratory disorders (e.g., severe sleep apnea syndrome); malignancy or immunocompromised status; uncontrolled diabetes (fasting blood glucose \\>12 mmol\u002FL).\n12. Pregnancy or lactation.\n13. Concurrent participation in another clinical trial, participation in any clinical trial within the past 90 days, or planned participation in another trial during the study period.\n14. Any contraindications to magnetic resonance imaging (e.g., metal implants, claustrophobia, respiratory or motor impairments).\n15. Inability to cooperate with study assessments.",{"count":377,"type":23},240,[26],"This clinical trial aims to investigate a novel non-pharmacological intervention, transcranial electrical stimulation (tES), for the treatment of comorbid depression and chronic pain. The primary objectives are to optimize neurostimulation parameters through a multicenter randomized controlled design and to elucidate the underlying neural circuit-immune interaction mechanisms of this comorbidity. Participants with comorbid depression and chronic pain will be randomly assigned to receive one of four interventions: (1) anodal tDCS unilateral hemispheric concurrent dual-site stimulation (a-tDCS UHCDS) targeting the left DLPFC and M1; (2) single-target anodal tDCS over the left DLPFC; (3) 40 Hz gamma transcranial alternating current stimulation (tACS); or (4) sham stimulation. The intervention period will last for 2 weeks, followed by a series of post-treatment follow-up assessments. Researchers will compare the changes in depression severity (e.g., assessed by HAMD-17) and pain intensity (e.g., NRS, BPI) across groups to evaluate the efficacy. Secondary outcomes include pain perception, quantitative sensory testing (QST), fMRI, MEG, metabolic markers, neurotransmitter and inflammatory biomarkers. This study aims to provide a precise, individualized therapeutic strategy, reduce reliance on pharmacotherapy, and promote the development of domestic high-end medical devices.",[381,382],"Depression Disorder","Chronic Pain",{"date":341,"type":40},{"date":186,"type":23},{"date":137,"type":23},{"name":46,"class":47},2,{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":57,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":407,"locationsCount":48},"100601681","the-efficacy-of-temporal-interference-stimulation-in-the-treatment-of-obsessive-compulsive-disorder-100601681","NCT07113652","The Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder","Exploring the Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* 18-50 years old\n* Diagnosis of OCD per DSM-5\n* Y-BOCS score ≥20\n* Have a documented history of at least two adequate trials of selective serotonin reuptake inhibitors (SSRIs). If currently receiving SSRI treatment, the dosage must be stable for at least 8 weeks prior to enrollment\n* With at least 9 years of education\n\nExclusion Criteria:\n\n* Any DSM-5 diagnosis other than OCD (except OCPD)\n* OCD symptoms too severe to complete assessments\n* Received electroconvulsive therapy (ECT) within the past 6 months\n* Received other forms of neuromodulation within the past 2 months（see Item 3 for ECT）\n* Severe medical illness or seizure risk (e.g., cardiovascular, respiratory conditions)\n* Neurological disorders or history of brain injury\u002Fsurgery\n* MRI-incompatible implants (e.g., pacemaker, stents, cochlear implants).\n* Current suicidal risk per investigator judgment\n* Pregnant or planning pregnancy during the study\n* Started structured OCD psychotherapy within 3 months, with expected change during treatment",{"count":396,"type":23},18,[26],"This study aims to evaluate the efficacy of Temporal Interference (TI) stimulation in treating patients with obsessive-compulsive disorder (OCD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) and electroencephalography (EEG).",[400],"Obsessive-Compulsive Disorder (OCD)","2026-03-07",{"date":403,"type":40},"2026-03-10",{"date":405,"type":40},"2025-08-17",{"date":91,"type":23},{"name":46,"class":47},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":167},"100625067","a-multicenter-observational-study-of-lemborexant-on-insomnia-patients-with-psychiatric-disorders-100625067","NCT07417813","A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders","A Multicenter, Prospective, Single-Arm, Observational Study on Effectiveness and Safety of Lemborexant on Insomnia Patients With Psychiatric Disorders","Inclusion Criteria:\n\n1. Aged 18 years and above, regardless of gender;\n2. Meet the DSM-5 diagnostic criteria for mental disorders (any type);\n3. Insomnia Severity Index (ISI) score ≥11;\n4. Have at least 7 hours of sleep time available;\n5. Able to complete the 2-month scale assessment and follow-up plan;\n6. Voluntarily sign the informed consent form;\n7. Intend to receive lemborexant treatment as judged by the clinicians\n\nExclusion Criteria:\n\n1. Mental disorder is in the acute phase as judged by clinical assessment, or the dose of other psychotropic drugs cannot be stabilized during the study;\n2. Concurrent use of ≥2 types of benzodiazepine receptor agonists (BZRAs) as insomnia treatment drugs;\n3. Previous continuous use of dual orexin receptor antagonist (DORA)-type drugs for \\>1 week;\n4. Clear suicide attempt\u002Fplan or high suicide risk as judged by the researcher;\n5. Pregnant or lactating women;\n6. Patients with narcolepsy;\n7. Patients with severe hepatic insufficiency;\n8. Currently accompanied by severe or unstable diseases of cardiovascular, respiratory, digestive and other systems;\n9. Other conditions deemed unsuitable for participation by the researcher",{"count":416,"type":23},121,"This study aims to evaluate the effectiveness and safety of lemborexant (a new dual orexin receptor antagonist) in the treatment of patients with mental disorders complicated with insomnia. The subjects are patients aged 18 years and above, who meet the DSM-5 diagnostic criteria for mental disorders and have an Insomnia Severity Index (ISI) score ≥11. They will receive lemborexant treatment for 8 weeks, with follow-up to observe the improvement of insomnia symptoms and adverse events, so as to provide real-world evidence for the clinical optimization of treatment regimens for insomnia comorbid with psychiatric disorders.",[419,420],"Insomnia","Psychiatric Disorders",[422,420,419,423,424],"Lemborexant","Dual Orexin Receptor Antagonist","Real-World Study","2026-02-13",{"date":427,"type":40},"2026-02-18",{"date":429,"type":40},"2026-01-24",{"date":367,"type":23},{"name":46,"class":47},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":17,"sex":56,"minAge":19,"maxAge":20,"enrollmentInfo":439,"targetDuration":4,"studyType":24,"phases":441,"briefSummary":442,"conditions":443,"keywords":447,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":387},"100597174","an-iso-principle-based-music-intervention-for-reducing-stress-anxiety-and-depression-100597174","NCT07055061","An ISO Principle-Based Music Intervention for Reducing Stress, Anxiety, and Depression","ISO4SAD","Inclusion Criteria:\n\n\\- Minimum of a secondary specialized school degree (vocational college) or higher\n\nExclusion Criteria:\n\n* Self-reported current or recent use of medication or history of surgical treatment\n* Self-reported history of psychiatric disorders\n* Self-reported hearing impairments\n* Female participants who are self-reported currently pregnant or breastfeeding",{"count":440,"type":23},2000,[26],"This study aims to evaluate the effectiveness of a music-based intervention, guided by the ISO principle, in reducing stress, anxiety and depression induced by work, family or others among adults. The ISO principle suggests that emotional regulation can be supported by gradually modifying the emotional characteristics of music to help individuals transition to a desired emotional state.\n\nParticipants in this study will be randomly assigned to either a music intervention group or a control group. The intervention group will receive personalized music playlists designed to help reduce stress, anxiety and depression. The control group will not receive any music intervention during the same period.\n\nOutcomes will be measured using self-report questionnaires assessing stress, emotional state, and well-being. The study is designed to contribute to the development of accessible, non-invasive stress management tools using music as a behavioral intervention.",[444,445,446],"Stress","Anxiety","Depression in Adults",[448,449,450],"music intervention","emotion regulation","ISO principle","2026-02-12",{"date":453,"type":40},"2026-02-17",{"date":455,"type":40},"2024-04-23",{"date":457,"type":23},"2026-12-12",{"name":46,"class":47},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":17,"sex":56,"minAge":465,"maxAge":19,"enrollmentInfo":466,"targetDuration":4,"studyType":24,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":48},"100620917","a-study-to-evaluate-the-effectiveness-of-group-gaming-interventions-for-individuals-with-problematic-gaming-behavior-and-gaming-disorder-100620917","NCT07363850","A Study to Evaluate the Effectiveness of Group Gaming Interventions for Individuals With Problematic Gaming Behavior and Gaming Disorder.","Inclusion Criteria:\n\n* (1) Clinical diagnosis of hazardous gaming defined in the ICD-11 (2) Fully comprehending the research's purpose and procedures and signing the informed consent\n\nExclusion Criteria:\n\n* (1)Serious physical illness or intellectual disability (2) Clinical diagnosis of gaming disorder (3) Not completing all the interventions or assessments","12 Years",{"count":467,"type":23},100,[26],"This is a randomized, parallel-group, two-arm study design registered with the Chinese Clinical Trial Registry. The study divides participants into an intervention group and a control group in the same ratio. The participants in the intervention group will receive a series of game-based activities and treatment. Firstly, we will distribute the recruitment advertisements for this intervention program in the school, including the project introduction, registration code, and contact details. Secondly, if students are interested in this project, they need to screen the code, and completely fill in personal information, and the screening questionnaire. Thirdly, students reaching the inclusion criteria and their parents will be invited to participate in a project briefing session and obtain their informed consent. Lastly, three times assessments in the whole process will be conducted, preintervention(T0), post-intervention(T1), and at a three-month(T3) follow-up. Importantly, participants can quit the project at any time during the whole process.",[471],"Gaming Disorder",[471],"2026-01-14",{"date":475,"type":40},"2026-01-23",{"date":477,"type":40},"2025-10-01",{"date":367,"type":23},{"name":46,"class":47},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":17,"sex":56,"minAge":19,"maxAge":20,"enrollmentInfo":487,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":48},"100616902","validation-of-the-accuracy-of-an-ai-based-system-for-diagnosing-anxiety-disorders-100616902","NCT07311655","Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders","Accuracy of an Artificial Intelligence-Based System for Diagnosing Anxiety Disorders: A Paired Comparison With Psychiatrist Clinical Diagnoses","1. Subjects with anxiety disorders\n\n   * Inclusion Criteria:\n\n     * In accordance with ICD-11 for Anxiety Disorders;\n     * Between the ages of 18-60;\n     * Ability to use computers or smartphone;\n     * Native Chinese speaker;\n     * Signing informed consent.\n   * Exclusion Criteria:\n\n     * With severe psychiatric symptoms requiring hospitalization, or unable to complete the required assessment and treatment;\n     * With a high risk of suicide or self-injury;\n     * With severe physical diseases, central nervous system diseases, or substance abuse;\n     * With intellectual, visual, or auditory impairments that affect their ability to interact with aided-diagnostic systems.\n2. Health Control\n\n   * Inclusion Criteria:\n\n     * Not meet ICD-11 criteria for Mental Disorders;\n     * Between the ages of 18-60;\n     * Ability to use computers or smartphone;\n     * Native Chinese speaker;\n     * Signing informed consent.\n   * Exclusion Criteria:\n\n     * With mental illness, or unable to complete the required assessment and treatment;\n     * With severe physical diseases, central nervous system diseases, or substance abuse;\n     * With intellectual, visual, or auditory impairments that affect their ability to interact with aided-diagnostic systems.\n3. Psychiatrist\n\n   * Inclusion Criteria:\n\n     * Over 18 years old;\n     * A minimum of three years' experience in anxiety and other mental health fields;\n     * Intermediate or higher professional title;\n     * Currently employed in the selected test region;\n     * Signing informed consent.",{"count":467,"type":23},"The trial aimed to evaluate the efficacy of an artificial intelligence-based system for diagnosing anxiety disorders. Specifically, it sought to determine whether the system's assessment validity is non-inferior to that of psychiatric specialists.",[290],"2025-12-29",{"date":492,"type":40},"2025-12-31",{"date":494,"type":23},"2026-02-01",{"date":496,"type":23},"2026-03-15",{"name":46,"class":47},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":17,"sex":56,"minAge":19,"maxAge":20,"enrollmentInfo":505,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":511,"leadSponsor":512,"locationsCount":48},"100616903","validation-of-the-accuracy-of-an-ai-based-system-for-diagnosing-depressive-disorders-100616903","NCT07311668","Validation of the Accuracy of an AI-Based System for Diagnosing Depressive Disorders","Accuracy of an Artificial Intelligence-Based System for Diagnosing Depressive Disorders: A Paired Comparison With Psychiatrist Clinical Diagnoses","1. Subjects with anxiety disorders （1）Inclusion Criteria:\n\n   * In accordance with ICD-11 for Depressive Disorders;\n   * Between the ages of 18-60;\n   * Ability to use computers or smartphone;\n   * Native Chinese speaker;\n   * Signing informed consent. （2）Exclusion Criteria:\n   * With severe psychiatric symptoms requiring hospitalization, or unable to complete the required assessment and treatment;\n   * With a high risk of suicide or self-injury;\n   * With severe physical diseases, central nervous system diseases, or substance abuse;\n   * With intellectual, visual, or auditory impairments that affect their ability to interact with aided-diagnostic systems.\n2. Health Control （1）Inclusion Criteria:\n\n   * Not meet ICD-11 criteria for Mental Disorders;\n   * Between the ages of 18-60;\n   * Ability to use computers or smartphone;\n   * Native Chinese speaker;\n   * Signing informed consent. （2）Exclusion Criteria:\n   * With mental illness, or unable to complete the required assessment and treatment;\n   * With severe physical diseases, central nervous system diseases, or substance abuse;\n   * With intellectual, visual, or auditory impairments that affect their ability to interact with aided-diagnostic systems.\n3. Psychiatrist （1）Inclusion Criteria:\n\n   * Over 18 years old;\n   * A minimum of three years' experience in anxiety and other mental health fields;\n   * Intermediate or higher professional title;\n   * Currently employed in the selected test region;\n   * Signing informed consent.",{"count":467,"type":23},"The trial aimed to evaluate the accuracy of an artificial intelligence-based system for diagnosing depressive disorders. Specifically, it sought to determine whether the system's assessment validity is non-inferior to that of psychiatric specialists.",[508],"Depressive Disorder",{"date":492,"type":40},{"date":494,"type":23},{"date":496,"type":23},{"name":46,"class":47},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":17,"sex":56,"minAge":258,"maxAge":121,"enrollmentInfo":519,"targetDuration":4,"studyType":24,"phases":520,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":48},"100615074","neural-mechanisms-of-temporal-interference-stimulation-on-improving-social-reward-function-in-depression-100615074","NCT07287878","Neural Mechanisms of Temporal Interference Stimulation on Improving Social Reward Function in Depression","Inclusion Criteria:\n\n* 16-60 years old;\n* Meeting with the criteria of major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5;\n* Scored 20 or higher on the Hamilton's Depression Scale with 24 items (HAMD-24);\n* With enough audio-visual ability and comprehensive ability to accomplish the visits;\n* Be necessary and suitable to accept the treatment of antidepressants;\n* Scored less than 14 on Hamilton's Anxiety Scale (HAMA) and scored less than 14 on the Hypomania Symptom Checklist-32 (HCL-32);\n* With 2 or more atypical symptoms including significant weight gain or increase in appetite, hypersomnia, leaden paralysis, and a long-standing pattern of interpersonal rejection sensitivity that results in significant social or occupational impairment.\n\nExclusion Criteria:\n\n* Severe medical or neurological problems;\n* Previous mania or hypomania episodes;\n* Female patients who are pregnant, planning to be pregnant or breastfeeding;\n* Actively suicide ascertained by research psychiatrist or 3rd item of HAMD scored≥3(suicidality);\n* Had ECT, MECT or rTMS in the past 6 months;\n* Experienced severe personality disorder, mental retardation, anorexia\u002F bulimia nervosa.",{"count":308,"type":23},[26],"Major depressive disorder (MDD) is a mood disorder characterized primarily by low mood, diminished interest, and reduced energy. Traditional views considered depression a non-degenerative condition; however, recent epidemiological studies have revealed its significant association with impaired social functioning. Data indicate that 59.3% of patients with depression experience social dysfunction of varying severity \\[1\\], particularly manifesting as difficulties in social interaction and relationship maintenance \\[2\\]. Therefore, investigating the mechanisms underlying social dysfunction is of great importance for promoting functional recovery in MDD, and dysfunction within the social reward system may represent a core factor, though the specific neural mechanisms remain unclear.\n\nThe ultimate goal of understanding the neural mechanisms underlying social reward impairment in depressed patients is to improve therapeutic outcomes. Temporal Interference (TI) stimulation, as a non-invasive deep brain stimulation technique, utilizes high-frequency current differentials to generate low-frequency amplitude-modulated electric fields, enabling precise targeting of deep brain regions. This study employs multimodal assessment methods-such as functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and specific cognitive-behavioral tasks-combined with TI stimulation to observe immediate changes in functional connectivity, neural activity, and related cognitive functions (e.g., decision-making, memory) across participant groups. The research aims to elucidate the roles of the parahippocampal gyrus, orbitofrontal cortex, and striatum in social reward impairment in depression, and to explore circuit-based intervention targets, thereby providing novel strategies for the recovery of social functioning in MDD.",[523],"Depression","2025-12-17",{"date":526,"type":40},"2025-12-24",{"date":528,"type":40},"2025-11-15",{"date":530,"type":23},"2026-07-10",{"name":46,"class":47},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":17,"sex":56,"minAge":539,"maxAge":19,"enrollmentInfo":540,"targetDuration":4,"studyType":24,"phases":542,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":48},"100611304","non-inferiority-of-virtual-vs-traditional-methods-in-adolescent-mental-health-literacy-100611304","NCT07238842","Non-inferiority of Virtual vs. Traditional Methods in Adolescent Mental Health Literacy","A Non-inferiority Study of the Virtual Agent-based Versus Teacher-led Psychological Literacy Enhancement Method in Improving Adolescents' Mental Health Literacy","Inclusion Criteria:\n\n1. Age between 11 and 18 years inclusive.\n2. Able to fluently operate a computer or smartphone.\n3. Possess normal language expression and reading comprehension abilities.\n4. Voluntarily agree to participate in the study and provide signed informed consent (and parental consent where required by local regulations).\n\nExclusion Criteria:\n\n1. Diagnosed with a psychiatric disorder that impairs the ability to complete assessments or participate in the intervention.\n2. Suffering from a severe physical illness, central nervous system disease, or substance use disorder that could interfere with study participation or outcomes.","11 Years",{"count":541,"type":23},360,[26],"The goal of this clinical trial is to determine whether a digital psychological literacy program delivered by an AI-powered virtual agent is non-inferior to traditional teacher-led instruction in improving mental health literacy among adolescents. The study focuses on middle and high school students aged 11 to 18 years attending a school in Shanghai, China, including those with varying levels of emotional well-being but excluding those with diagnosed psychiatric disorders or severe physical illness.\n\nThe main questions it aims to answer are:\n\nIs the virtual agent-delivered psychological literacy program as effective as teacher-led instruction in improving adolescents' mental health literacy? Does the virtual agent intervention lead to comparable or better outcomes in secondary measures such as depression, anxiety, psychological resilience, sleep quality, and digital well-being?\n\nResearchers will compare students receiving 6 weekly sessions from a virtual digital agent to students receiving the same curriculum delivered by trained psychology teachers to see if the AI-based approach achieves similar improvements in mental health knowledge, attitudes, and help-seeking behaviors.\n\nParticipants will:\n\nComplete online assessments at baseline, week 3, week 6 and week 18 covering mental health literacy (UMHL-A), depression (PHQ-9), anxiety (GAD-7), psychological resilience (RSCA), and other well-being indicators Attend one 45-60 minute session per week for 6 weeks, either interacting with the virtual agent or participating in a teacher-led class Optionally take part in a brief satisfaction survey and\u002For a focus group interview after the intervention to share their experiences",[545],"Mental Health Literacy","2025-11-16",{"date":548,"type":40},"2025-11-20",{"date":550,"type":40},"2025-05-16",{"date":552,"type":23},"2026-02-28",{"name":46,"class":47},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":20,"enrollmentInfo":561,"targetDuration":4,"studyType":24,"phases":562,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":574,"locationsCount":48},"100610435","high-intensity-alternating-current-stimulation-as-a-neuromodulation-therapy-for-alcohol-use-disorder-a-pilot-study-100610435","NCT07227545","High Intensity Alternating Current Stimulation as a Neuromodulation Therapy for Alcohol Use Disorder: A Pilot Study","HITACS-AUD","Inclusion Criteria:\n\n* Education level of junior high school or above, capable of completing questionnaires and behavioral tests;\n* Aged 18-60 years;\n* Meet DSM-5 diagnostic criteria for Alcohol Use Disorder;\n* No abnormal findings on physical examination;\n* Agree to participate in follow-up assessments;\n* No contraindications for MRI scanning.\n\nExclusion criteria:\n\n* Have impaired intelligence (Intelligence Quotient\\\u003C70);\n* Prior tDCS or TMS treatment within the past 3 months;\n* Contraindications for TMS therapy (e.g., intracranial metal implants, history of traumatic brain injury, skull defects, cardiac pacemakers, cardiovascular diseases, or epilepsy);\n* Severe somatic diseases or major organ dysfunction;\n* Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).",{"count":396,"type":23},[26],"This study aims to explore the efficacy of high intensity transcranial alternating current stimulation on individuals with alcohol use disorders. Utilizing a one-arm pilot study design, participants will undergo transcranial alternating current stimulation.",[565],"Alcohol Use Disorder (AUD)",[567],"High-Intensity Transcranial Alternating Current Stimulation, Alcohol Use Disorder","2025-11-10",{"date":570,"type":40},"2025-11-12",{"date":572,"type":23},"2025-12-01",{"date":367,"type":23},{"name":46,"class":47},""]